Genzyme Sets Sights On 13 Drug Approvals By 2012; Only 2 Are NMEs
This article was originally published in Pharmaceutical Approvals Monthly
Only two new molecular entities are included in Genzyme's plan for 13 drug approvals between now and 2012, CEO Henri Termeer said during the company's annual analyst and investor day May 7
You may also be interested in...
Findings from additional mipomersen clinical trials announced by Genzyme and Isis Jan. 12 will aid in the design of a subsequent outcomes trial FDA has requested for the cholesterol-lowering drug candidate
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.